Limits...
Trichomegaly and scalp hair changes following treatment with erlotinib in pulmonary adenocarcinoma patients: A case report and literature review

View Article: PubMed Central - PubMed

ABSTRACT

Erlotinib is among the oral EGFR-tyrosine kinase inhibitors used to treat non-small cell lung cancer. The common side effects of erlotinib include acne form rash and diarrhea. Eyelash trichomegaly and alterations of scalp hair are rarely observed symptoms. In the present study, we report changes in eyelash trichomegaly and scalp hair in six cases of pulmonary adenocarcinoma patients that had been administered erlotinib. The symptoms of eyelash trichomegaly include curly, irregular, excessively long and brittle eyelashes, and alterations of scalp hair include curly or straight, brittle, fine or rigid, reduced growth rate and volume. Since these side effects does not substantially impact patient quality of life, no treatments were administered. These changes in eyelashes and scalp hair gradually disappeared after withdrawal of erlotinib.

No MeSH data available.


Alteration of scalp hair in case 6. Patient's hair became straight from curly during treatment with erlotinib. (A) Prior to and (B) after receiving erlotinib.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4998076&req=5

f4-etm-0-0-3460: Alteration of scalp hair in case 6. Patient's hair became straight from curly during treatment with erlotinib. (A) Prior to and (B) after receiving erlotinib.

Mentions: A 60-year-old male patient with a diagnosis of stage cT4N2M1b lung adenocarcinoma primarily located in the left hilar and metastasis to mediastinal lymph node and bone tissues had a missense mutation at exon 21 of EGFR [c.2573T>G (p.L858R)] by direct Sanger sequencing test. The patient received maintenance therapy with erlotinib (150 mg, daily) from December 2, 2012 as second line therapy. His disease remained stable as of December 22, 2014, and the PFS of erlotinib is 25 months. During the erlotinib treatment, the patient complained of severe skin rashes and acne on his face, neck, chest and scalp, which were not controlled well with topical therapy. In addition, the patient experienced slight diarrhea. The erlotinib administration was reduced from daily to 5–6 times per week with unchanged per dose (150 mg), and the side effects mentioned above improved. In addition, the patient exhibited elongated, curly and irregular growth of his eyelashes, and his scalp hair volume reduced at 6 months after initiating erlotinib treatment. Notably, the patients hair became straight from curly after 6 months of treatment with erlotinib (Fig. 4). No management was performed since the side effects did not impact the patient's quality of life.


Trichomegaly and scalp hair changes following treatment with erlotinib in pulmonary adenocarcinoma patients: A case report and literature review
Alteration of scalp hair in case 6. Patient's hair became straight from curly during treatment with erlotinib. (A) Prior to and (B) after receiving erlotinib.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4998076&req=5

f4-etm-0-0-3460: Alteration of scalp hair in case 6. Patient's hair became straight from curly during treatment with erlotinib. (A) Prior to and (B) after receiving erlotinib.
Mentions: A 60-year-old male patient with a diagnosis of stage cT4N2M1b lung adenocarcinoma primarily located in the left hilar and metastasis to mediastinal lymph node and bone tissues had a missense mutation at exon 21 of EGFR [c.2573T>G (p.L858R)] by direct Sanger sequencing test. The patient received maintenance therapy with erlotinib (150 mg, daily) from December 2, 2012 as second line therapy. His disease remained stable as of December 22, 2014, and the PFS of erlotinib is 25 months. During the erlotinib treatment, the patient complained of severe skin rashes and acne on his face, neck, chest and scalp, which were not controlled well with topical therapy. In addition, the patient experienced slight diarrhea. The erlotinib administration was reduced from daily to 5–6 times per week with unchanged per dose (150 mg), and the side effects mentioned above improved. In addition, the patient exhibited elongated, curly and irregular growth of his eyelashes, and his scalp hair volume reduced at 6 months after initiating erlotinib treatment. Notably, the patients hair became straight from curly after 6 months of treatment with erlotinib (Fig. 4). No management was performed since the side effects did not impact the patient's quality of life.

View Article: PubMed Central - PubMed

ABSTRACT

Erlotinib is among the oral EGFR-tyrosine kinase inhibitors used to treat non-small cell lung cancer. The common side effects of erlotinib include acne form rash and diarrhea. Eyelash trichomegaly and alterations of scalp hair are rarely observed symptoms. In the present study, we report changes in eyelash trichomegaly and scalp hair in six cases of pulmonary adenocarcinoma patients that had been administered erlotinib. The symptoms of eyelash trichomegaly include curly, irregular, excessively long and brittle eyelashes, and alterations of scalp hair include curly or straight, brittle, fine or rigid, reduced growth rate and volume. Since these side effects does not substantially impact patient quality of life, no treatments were administered. These changes in eyelashes and scalp hair gradually disappeared after withdrawal of erlotinib.

No MeSH data available.